12967_2021_2789_MOESM2_ESM.tif (139.64 kB)
Additional file 2 of Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
figure
posted on 2021-03-21, 04:36 authored by Xuejie Jiang, Ling Jiang, Jiaying Cheng, Fang Chen, Jinle Ni, Changxin Yin, Qiang Wang, Zhixiang Wang, Dan Fang, Zhengshan Yi, Guopan Yu, Qingxiu Zhong, Bing Z. Carter, Fanyi MengAdditional file 2: Fig. S2. Chidamide doesn’t sensitize normal CD45+ and CD34+cells to adriamycin. Bone marrow samples from healthy donors were treated with chidamide (1.00 μmol/L), adriamycin (0.13 μmol/L) or both for 48 hours. Apoptosis in CD45+ and CD34+ cells was determined by flow cytometry. Ctrl, control; Chi, chidamide; ADM, adriamycin; Comb, combination.
